INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
Advanced Malignancies|Metastatic Cancer
DRUG: INCAGN01876|DRUG: Epacadostat|DRUG: Pembrolizumab
Phase 1 and Phase 2: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability], A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after the first dose of study treatment., Screening through 60 days after end of treatment, up to approximately 18 months|Phase 1 and Phase 2 : ORR Based on RECIST v1.1 and mRECIST, Defined as the percentage of participants having a CR or PR based on investigator assessment per RECIST v1.1., Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months|Phase 2: Complete Response Rate (CRR) Based on RECIST v1.1, Defined as the percentage of checkpoint inhibitor-naive melanoma participants who have a CR based on investigator assessment per RECIST v1.1, Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months
Phase 1 & Phase 2: Disease Control Rate Based on RECIST v1.1 and mRECIST, Defined as the percentage of participants having CR, PR, or stable disease (SD) based on investigator assessment per RECIST v1.1., Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months.|Phase 1 & Phase 2: Duration of Response Based on RECIST v1.1 and mRECIST, Defined as the time from the earliest date of disease response (CR or PR) until earliest date of disease progression or death due to any cause., Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months|Phase 1 & Phase 2: Duration of Disease Control Based on RECIST v1.1 and mRECIST, Defined as time from first report of SD or better until disease progression or death from any cause., Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months|Phase 1 & Phase 2: Progression-free Survival Based on RECIST v1.1 and mRECIST, Defined as the time from the start of combination therapy until the earliest date of disease progression or death due to any cause., Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months|Phase 1 & Phase 2: Overall Survival, Defined as the time from the start of combination therapy until death due to any cause., At 1 year and 2 years.
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.